Cargando…

Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach

Owing to their unique functions in regulating glucose, lipid and cholesterol metabolism, PPARs (peroxisome proliferator-activated receptors) have drawn special attention for developing drugs to treat type-2 diabetes. By combining the lipid benefit of PPAR-alpha agonists (such as fibrates) with the g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Ying, Wang, Shu-Qing, Xu, Wei-Ren, Wang, Run-Ling, Chou, Kuo-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369836/ https://www.ncbi.nlm.nih.gov/pubmed/22685582 http://dx.doi.org/10.1371/journal.pone.0038546

Ejemplares similares

Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method
por: Li, Xiao-Bo, et al.
Publicado: (2011)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics
por: Liu, Lei, et al.
Publicado: (2013)

Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor δ Agonist
por: Lee, Su-Jeong, et al.
Publicado: (2018)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

Antcins, triterpenoids from Antrodia cinnamomea, as new agonists for peroxisome proliferator-activated receptor α
por: Wang, Yu-Jen, et al.
Publicado: (2018)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
por: Aljada, Ahmad, et al.
Publicado: (2009)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
por: Zhu, Yun-Xia, et al.
Publicado: (2016)

Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver
por: Ferguson, Laura B., et al.
Publicado: (2018)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
por: Chen, Yan, et al.
Publicado: (2017)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells?
por: Alsarra, Ibrahim A, et al.
Publicado: (2006)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?
por: Freitag, Caroline M., et al.
Publicado: (2014)

Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization
por: Tobita, Yutaro, et al.
Publicado: (2020)

Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing
por: Tobita, Yutaro, et al.
Publicado: (2021)

Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
por: Miyachi, Hiroyuki
Publicado: (2021)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Molecular Recognition of Agonist and Antagonist for Peroxisome Proliferator-Activated Receptor-α Studied by Molecular Dynamics Simulations
por: Liu, Mengyuan, et al.
Publicado: (2014)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression
por: Burrage, Peter S, et al.
Publicado: (2008)

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
por: Cariou, Bertrand, et al.
Publicado: (2013)

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
por: Lee, Mi Young, et al.
Publicado: (2012)

Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction
por: Park, Jeong Rang, et al.
Publicado: (2016)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome Proliferator-Activated Receptor α Agonist and Its Target Nanog Cooperate to Induce Pluripotency
por: Lee, Jungwoon, et al.
Publicado: (2018)

Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo
por: Du, Lingyao, et al.
Publicado: (2017)

A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts
por: Assmann, Anna Kathrin, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria
por: Garsen, Marjolein, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rdtancrhrkal9p6bvu9fcf1ra2